







# Intermittent antegrade warm blood versus cold blood cardioplegia in children undergoing open heart surgery

<b>Submission date</b> 19/03/2018	<b>Recruitment status</b> No longer recruiting	 Prospectively registered
		 Protocol added
<b>Registration date</b> 05/04/2018	<b>Overall study status</b> Completed	 SAP not yet added
		 Results added
<b>Last Edited</b> 20/02/2023	<b>Condition category</b> Surgery	 Raw data not yet added
		 Study completed

## Plain English Summary

### Background and study aims

Congenital heart disease is a problem in the structure of the heart that is present at birth. It is not uncommon and morbidity (illness) following heart surgery in children remains significant. Surgical repair of congenital heart defects usually requires the heart to be stopped using a cold solution containing potassium (cardioplegia) which protects the heart and keeps it still when operating. Cold cardioplegia solutions may have negative effects on the recovery of the heart after surgery in adults. However, very little is known about the effects of using warm cardioplegia solutions in children. The aim of this study is to compare warm and cold cardioplegia in children undergoing open heart surgery. Temperature monitoring is essential and always measured during the treatment of critically ill children. Rectal temperature monitoring is currently the most commonly used method for estimation of core body temperature in ill children. Multiple studies in adults and children have questioned the accuracy of rectal temperature monitoring when compared to pulmonary artery or urinary catheter monitoring. However, these studies are limited by small numbers. The study therefore also compares measurements of core body temperature obtained using a temperature sensing urinary catheter, a rectal temperature probe, and other temperature measuring devices such as axillary (armpit), oral (mouth), aural (ear) and oesophageal (food pipe) probes.

### Who can participate?

Patients undergoing a congenital heart operation requiring cardiopulmonary bypass and cardioplegic arrest

### What does the study involve?

Participants are randomly allocated to one of two groups to be treated with either warm or cold cardioplegia solutions to stop and protect the heart. Recovery and complications after surgery are compared between the two groups.

### What are the possible benefits and risks of participating?

Participants in the cold cardioplegia group receive the same surgical procedure as patients not

participating in the study and receive the same benefits inherent in cardiac surgery. Participants in the warm cardioplegia group receive the same benefits. Recent evidence suggests that warm cardioplegia is safe in children and may improve outcomes.

Where is the study run from?  
Bristol Royal Hospital for Children (UK)

When is the study starting and how long is it expected to run for?  
December 2017 to September 2021 (updated 30/03/2021, previously: February 2021 (updated 29/06/2020, previously: August 2020))

Who is funding the study?  
British Heart Foundation (UK)

Who is the main contact?  
Ms Lucy Dabner, thermic3-trial@bristol.ac.uk  
(updated 29/06/2020, previously: Miss Rachael Heys, rh13369@bristol.ac.uk)

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Ms Lucy Dabner

**Contact details**  
Bristol Trials Centre - Clinical Trials and Evaluation Unit  
University of Bristol Medical School  
Level 7  
Bristol Royal Infirmary  
Upper Maudlin Street  
Bristol  
United Kingdom  
BS2 8HW  
+44 (0)117 342 2374  
thermic3-trial@bristol.ac.uk

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**  
211278

**ClinicalTrials.gov number**

**Protocol/serial number**  
37109, IRAS 211278

# Study information

## Scientific Title

Intermittent antegrade warm blood versus cold blood cardioplegia in children undergoing open heart surgery: a randomised controlled trial (THERMIC-3)

## Acronym

THERMIC-3

## Study hypothesis

Congenital heart disease is not uncommon and morbidity following cardiac surgery in children remains significant. Surgical repair of congenital heart defects usually requires the heart to be stopped using a cold solution containing potassium (cardioplegia) which protects the heart and keeps it still when operating. Cold cardioplegia solutions may have deleterious effects on the recovery of the heart after surgery in adults. However, very little is known about the effects of using warm cardioplegia solutions in children. Therefore, children undergoing open heart surgery will be assigned by chance to one of two groups, using either warm or cold cardioplegia solutions to stop and protect the heart. Clinical and biochemical measures of recovery and complications following surgery will be compared between the two groups.

A sub-study will also look at methods for measuring core body temperature monitoring in children undergoing cardiac surgery with cardiopulmonary bypass. Temperature monitoring is an essential and a universally measured sign in the management of critically ill children. Rectal temperature monitoring is currently the most commonly used method for estimation of the core body temperature in ill children. Multiple studies in adults and children have questioned the accuracy of rectal temperature monitoring when compared to pulmonary artery or urinary catheter monitoring. However, these studies are limited by small numbers. The sub-study is a proof of concept study which will compare measurements of core body temperature obtained using a temperature sensing urinary catheter and a rectal temperature probe and other temperature measuring devices such as axillary, oral, aural and oesophageal probes.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

London Central Research Ethics Committee, 07/03/2018, ref: 18/LO/0205

## Study design

Randomised; Interventional; Design type: Process of Care, Surgery

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

## Treatment

### Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

### Condition

Congenital malformations of cardiac chambers and connections

### Interventions

Eligible patients requiring congenital heart operations who give consent will be randomised to receive either warm blood cardioplegia or cold blood cardioplegia during their cardiac surgery. Clinical and biochemical measures of recovery and complications following surgery will be compared between the two groups.

### Sub-study:

The sub-study is a proof of concept study which will compare measurements of core body temperature obtained using a temperature sensing urinary catheter and a rectal temperature probe and investigate the lag in changes in temperature with the two methods during therapeutic or pathological rapid changes in body core temperature. It will also investigate changes in the relationship between urinary bladder and rectal temperature measurements during low urinary output state (defined as urine output of less than 0.5ml/kg/hr) and compare the accuracy of these measurements with other temperature measuring devices such as axillary, oral, aural and oesophageal probes in the same cohort.

### Intervention Type

Procedure/Surgery

### Primary outcome measure

Troponin T (cTnT) levels over the first 48 postoperative hours

### Secondary outcome measures

Current secondary outcome measures as of 18/03/2020:

1. Cardiac function, assessed by measuring cardiac output and cardiac index. Central venous saturations (ScvO<sub>2</sub>), arterial saturations, base deficit & blood lactate will also be recorded as indirect measures of cardiac index. Central venous saturations (ScvO<sub>2</sub>), arterial saturations, base deficit and blood lactate recorded as indirect measures of cardiac index up to 48 hours postoperatively
2. Routine blood gas and blood sample/test results measured before, during and after surgery (up to 48 hours postoperatively). Results collected will include pH, PO<sub>2</sub>, PCO<sub>2</sub>, base excess and lactate from blood gases and serum creatinine and urea nitrogen (measures of renal function), c-reactive protein (CRP), haemoglobin (Hb), haematocrit (Hct), white cell count (WCC) and alanine aminotransferase (ALT) from blood samples.
3. Renal function measured by urinary albumin, urinary creatinine, retinal binding protein (RBP), N-acetyl-β-glucosaminidase (NAG) and neutrophil gelatinase-associated lipocalin (n-GAL) in urine samples, measured before surgery and at 4 hours, 24 hours and 48 hours postoperatively
4. Cardiac and electrical activity on removal off cross clamp and chest closure (arrhythmias including; atrial fibrillation/flutter, ventricular tachycardia, ventricular fibrillation, nodal, junctional ectopic tachycardia (JET) or AV block)
5. Postoperative blood loss in the first 12 hours
6. New onset of arrhythmia post-operatively (either supraventricular tachycardia/atrial

- fibrillation or ventricular fibrillation/ventricular tachycardia, JET or heart block)
7. Vasoactive-inotrope score (VIS) over the first 48 hours after admission to PICU
  8. Intubation time
  9. Time from return from theatre until fit for discharge to the ward/high dependency unit (HDU) from the paediatric intensive care unit (PICU). Fit for discharge to the ward/HDU will reflect current HDU/ward admission criteria.
  10. Chest and wound infections, recorded post-operatively
  11. All-cause mortality to 3 months post-surgery
  12. Length of postoperative hospital stay
  13. Myocardial injury at the molecular and cellular level (e.g. transcriptomics, proteomics and metabolomics) measured in samples considered clinical waste during surgery
  14. Body temperature from rectal, esophageal and urinary bladder and from oral, axillary and aural sites where possible for 8 hours after surgery (sub-study)

Previous secondary outcome measures:

1. Cardiac function, assessed by measuring cardiac output, cardiac index and myocardial contractility using trans-oesophageal echocardiography (TOE) during surgery and transthoracic echocardiography (TTE) pre-operatively and at 24 hours postoperatively. Central venous saturations (ScvO<sub>2</sub>), arterial saturations, base deficit and blood lactate recorded as indirect measures of cardiac index up to 48 hours postoperatively
2. Routine blood gas and blood sample/test results measured before, during and after surgery (up to 48 hours postoperatively)
3. Cerebral function/injury measured by Glial Fibrillary Acidic Protein (GFAP) before, during surgery and at 2 hours, 6 hours, 24 hours and 48 hours postoperatively
4. Renal function measured by urinary albumin, urinary creatinine, retinal binding protein (RBP), N-acetyl- $\beta$ -glucosaminidase (NAG) and neutrophil gelatinase-associated lipocalin (n-GAL) in urine samples, measured before surgery and at 4 hours, 24 hours and 48 hours postoperatively
5. Cardiac and electrical activity on removal off cross clamp and chest closure (arrhythmias including; atrial fibrillation/flutter, ventricular tachycardia, ventricular fibrillation, nodal, junctional ectopic tachycardia (JET) or AV block)
6. Postoperative blood loss in the first 12 hours
7. New onset of arrhythmia post-operatively (either supraventricular tachycardia/atrial fibrillation or ventricular fibrillation/ventricular tachycardia, JET or heart block)
8. Vasoactive-inotrope score (VIS) over the first 48 hours after admission to PICU
9. Intubation time
10. Time from return from theatre until fit for discharge to the ward/high dependency unit (HDU) from the paediatric intensive care unit (PICU). Fit for discharge to the ward/HDU will reflect current HDU/ward admission criteria.
11. Chest and wound infections, recorded post-operatively
12. All-cause mortality to 3 months post-surgery
13. Length of postoperative hospital stay
14. Myocardial injury at the molecular and cellular level (e.g. transcriptomics, proteomics and metabolomics) measured in samples considered clinical waste during surgery
15. Body temperature from rectal, esophageal and urinary bladder and from oral, axillary and aural sites where possible for 8 hours after surgery (sub-study)

**Overall study start date**

01/12/2017

**Overall study end date**

30/09/2021

# Eligibility

## Participant inclusion criteria

Patients undergoing a congenital heart operation requiring CPB and cardioplegic arrest at the BRHC

## Participant type(s)

Patient

## Age group

Child

## Sex

Both

## Target number of participants

Planned Sample Size: 94; UK Sample Size: 94

## Total final enrolment

97

## Participant exclusion criteria

1. Patient weighing < 3 kg
2. Patient requires an emergency operation (patient with haemodynamic instability who require immediate surgical intervention defined as operation within 24 hours of admission)
3. Patient requires secundum atrial septal defect repair (ASD) as an isolated procedure
4. Patient judged pre-operatively by surgeon to require deep hypothermic circulatory arrest (e.g. aortic arch repair, repair of total anomalous pulmonary venous drainage (TAPVD), Norwood procedure)
5. Patient judged pre-operatively by the surgeon to require deep hypothermic CPB
6. Patient judged by the surgeon pre-operatively to be too complex. This could be procedure related or patient related (e.g. complex tailor made surgery; necrotising enterocolitis; pre-operative brain haemorrhage; or generalised bleeding state/ongoing major bleeding)
7. Patient of consenting/assenting age lacking capacity to consent/assent
8. Patient under the care of social services and/or parent/guardian unavailable for consent

For the sub-study, the following additional exclusion criteria will apply:

9. Patient aged < 4 months
10. Patient weighing < 6 kg
11. Patient has contraindication for urethral catheterisation due to urethral obstruction or haemorrhage.

## Recruitment start date

08/05/2018

## Recruitment end date

01/04/2020

## Locations

## **Countries of recruitment**

England

United Kingdom

## **Study participating centre**

**Bristol Royal Hospital for Children**

24 Upper Maudlin St

Bristol

United Kingdom

BS2 8BJ

## **Sponsor information**

### **Organisation**

University Hospitals Bristol NHS Foundation Trust

### **Sponsor details**

Research and Innovation

Level 3, Education Centre

Upper Maudlin Street

Bristol

England

United Kingdom

BS2 8AE

+44 (0)117 342 0233

abc@email.com

### **Sponsor type**

Hospital/treatment centre

### **ROR**

<https://ror.org/04nm1cv11>

## **Funder(s)**

### **Funder type**

Charity

### **Funder Name**

British Heart Foundation (BHF); Grant Codes: CH/1992027/7163 & CH/17/1/32804

## Alternative Name(s)

the\_bhf, The British Heart Foundation, BHF

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Trusts, charities, foundations (both public and private)

## Location

United Kingdom

# Results and Publications

## Publication and dissemination plan

The trialists plan to publish a protocol paper in the near future. The findings will be disseminated by the usual academic channels around one year after the overall trial end date, i.e. presentation at international meetings, as well as by peer-reviewed publications and through patient organisations and newsletters to patients, where available.

## Intention to publish date

31/03/2022

## Individual participant data (IPD) sharing plan

The data sharing plans for the current study are unknown and will be made available at a later date.

## IPD sharing plan summary

Data sharing statement to be made available at a later date

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>	protocol	14/10/2020	22/10/2020	Yes	No
<a href="#">Results article</a>		17/02/2023	20/02/2023	Yes	No
<a href="#">HRA research summary</a>			28/06/2023	No	No